7,652 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Acquired by SWP Financial LLC

SWP Financial LLC bought a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 7,652 shares of the biopharmaceutical company’s stock, valued at approximately $366,000.

Other institutional investors also recently added to or reduced their stakes in the company. GAMMA Investing LLC increased its stake in shares of Halozyme Therapeutics by 67.7% during the third quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 350 shares during the period. Toth Financial Advisory Corp acquired a new position in shares of Halozyme Therapeutics during the 3rd quarter valued at $57,000. FSC Wealth Advisors LLC bought a new stake in shares of Halozyme Therapeutics in the 3rd quarter worth $65,000. Park Place Capital Corp lifted its holdings in shares of Halozyme Therapeutics by 828.1% in the third quarter. Park Place Capital Corp now owns 1,355 shares of the biopharmaceutical company’s stock valued at $78,000 after buying an additional 1,209 shares during the period. Finally, CWM LLC boosted its stake in Halozyme Therapeutics by 77.5% during the third quarter. CWM LLC now owns 1,530 shares of the biopharmaceutical company’s stock valued at $88,000 after buying an additional 668 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on HALO shares. Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. JMP Securities increased their target price on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research note on Friday, November 1st. Piper Sandler lifted their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research report on Friday, January 10th. Wells Fargo & Company cut their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Finally, HC Wainwright lifted their target price on Halozyme Therapeutics from $68.00 to $70.00 and gave the stock a “buy” rating in a report on Friday, January 10th. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $60.89.

Insider Buying and Selling

In related news, Director Jeffrey William Henderson sold 10,000 shares of the company’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $50.01, for a total value of $500,100.00. Following the completion of the sale, the director now directly owns 43,611 shares in the company, valued at approximately $2,180,986.11. This represents a 18.65 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 2.40% of the stock is currently owned by corporate insiders.

Halozyme Therapeutics Stock Performance

Shares of HALO stock opened at $55.77 on Monday. Halozyme Therapeutics, Inc. has a fifty-two week low of $33.15 and a fifty-two week high of $65.53. The stock’s 50-day moving average is $49.59 and its two-hundred day moving average is $54.23. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. The firm has a market cap of $7.10 billion, a P/E ratio of 18.47, a PEG ratio of 0.42 and a beta of 1.24.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.